

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 15, 2002, 05:36:04 ; Search time 196.78 Seconds
(without alignments)
19148.005 Million cell updates/sec

Title: US-09-652-292-1

Perfect score: 4395

Sequence: 1 gaggggtctgcccagcc.....attatttgaaaaaaaaaa 4395

Scoring table: OLIGO_NUC

Gapop 60.0 , Gapext 60.0

Searched: 930621 seqs, 428662619 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1861242

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N.Geneseq_1101.*

1: /SID52/gcgdata/geneseq/geneseq/NA1980.DAT.*
2: /SID52/gcgdata/geneseq/geneseq/NA1981.DAT.*
3: /SID52/gcgdata/geneseq/geneseq/NA1982.DAT.*
4: /SID52/gcgdata/geneseq/geneseq/NA1983.DAT.*
5: /SID52/gcgdata/geneseq/geneseq/NA1984.DAT.*
6: /SID52/gcgdata/geneseq/geneseq/NA1985.DAT.*
7: /SID52/gcgdata/geneseq/geneseq/NA1986.DAT.*
8: /SID52/gcgdata/geneseq/geneseq/NA1987.DAT.*
9: /SID52/gcgdata/geneseq/geneseq/NA1988.DAT.*
10: /SID52/gcgdata/geneseq/geneseq/NA1989.DAT.*
11: /SID52/gcgdata/geneseq/geneseq/NA1990.DAT.*
12: /SID52/gcgdata/geneseq/geneseq/NA1991.DAT.*
13: /SID52/gcgdata/geneseq/geneseq/NA1992.DAT.*
14: /SID52/gcgdata/geneseq/geneseq/NA1993.DAT.*
15: /SID52/gcgdata/geneseq/geneseq/NA1994.DAT.*
16: /SID52/gcgdata/geneseq/geneseq/NA1995.DAT.*
17: /SID52/gcgdata/geneseq/geneseq/NA1996.DAT.*
18: /SID52/gcgdata/geneseq/geneseq/NA1997.DAT.*
19: /SID52/gcgdata/geneseq/geneseq/NA1998.DAT.*
20: /SID52/gcgdata/geneseq/geneseq/NA1999.DAT.*
21: /SID52/gcgdata/geneseq/geneseq/NA2000.DAT.*
22: /SID52/gcgdata/geneseq/geneseq/NA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	182	4.1	385	22	AAH50797 Human tumour assoc
2	126	2.9	452	22	AAI15064 Probe #4997 for ge
3	126	2.9	452	22	AAI36406 Probe #5092 used t
4	126	2.9	452	22	AAI04827 Probe #4818 used t
5	105	2.4	180	22	AAI24251 Probe #14184 for g
6	105	2.4	180	22	AAI49534 Probe #18220 used
7	105	2.4	180	22	AAI09811 Probe #9802 used t
8	50	1.1	17131	21	AAZ60888 DNA encoding a hum
9	48	1.1	454	21	AAA45104 Human secreted exp
10	48	1.1	21636	21	AAAS5966 Human G713 3'-end
11	46	1.0	241	22	AAF17845 Human breast cance

C 12	46	1.0	376	22	AAF65548	Novel human polynu
C 13	45	1.0	1242	20	AAH85026	Human secreted pro
C 14	44	1.0	545	22	AAH10383	Human cDNA clone (
C 15	44	1.0	2609	22	AAH17513	Human cDNA sequenc
C 16	43	1.0	122186	22	AAH89560	Human histone deac
C 17	42	1.0	2791	20	AAH80486	Human secreted pro
C 18	42	1.0	49999	20	AAZ23901	Human LOBO homolog
C 19	41	0.9	171	21	AAH28400	Human secreted pro
C 20	41	0.9	889	22	AAH72617	Human cervical can
C 21	41	0.9	2221	22	AAH13971	Human cDNA sequenc
C 22	41	0.9	2284	20	AAH80059	Human PRO361 nucle
C 23	41	0.9	2284	21	AAA49567	Human PRO361 cDNA.
C 24	41	0.9	2284	22	AAF44268	Human PRO361 nucle
C 25	41	0.9	2297	22	AAH18096	Human cDNA sequenc
C 26	41	0.9	2342	21	AAH59840	Human secreted pro
C 27	41	0.9	2407	22	AAH18551	Human cDNA sequenc
C 28	41	0.9	2418	21	AAH58593	Human PRO361 prote
C 29	41	0.9	6727	20	AAH02993	Human IL-1ra BAC c
C 30	41	0.9	122186	22	AAH89560	Human histone deac
C 31	40	0.9	300	20	AAZ13969	Human gene express
C 32	40	0.9	771	20	AAZ15472	Human gene express
C 33	40	0.9	1608	22	AAH17235	Human cDNA sequenc
C 34	40	0.9	1669	22	AAH26169	Human cytochrome P
C 35	40	0.9	1669	22	AAH26179	Human cytochrome P
C 36	40	0.9	3648	22	AAH18638	Human cDNA sequenc
C 37	40	0.9	7505	20	AAH83949	Bacterial artifci
C 38	39	0.9	1133	21	AAH59501	Human secreted pro
C 39	39	0.9	6374	22	AAH09491	Human SGP006 phosp
C 40	38	0.9	336	21	AAH16012	Human colon cancer
C 41	38	0.9	3023	20	AAH03036	Human IL-1ra BAC c
C 42	38	0.9	24025	17	AAH17455	Mutated BRCA1 geno
C 43	38	0.9	24025	17	AAH17515	Mutated BRCA1 geno
C 44	38	0.9	24026	17	AAH26112	BRCA1, human breas
C 45	38	0.9	24026	17	AAH17512	Mutated BRCA1 geno

ALIGNMENTS

RESULT 1
AAH50797/c
ID AAH50797 standard; cDNA; 385 BP.
XX AAH50797;
AC AAH50797;
DT 23-AUG-2001 (first entry)
XX Human tumour associated cDNA #126.
DE Human; cancer specific gene expression; gene therapy;
KW age related differential expression; ss.
XX Homo sapiens.
OS
XX
PN WO200136685-A2.
XX
PD 25-MAY-2001.
XX
PP 17-NOV-2000; 2000WO-US31809.
XX
PR 17-NOV-1999; 99US-0166056.
PR 17-NOV-1999; 99US-0166106.
XX (NYXI-) NYXIS NEURO THERAPIES INC.
XX Kroes RA, Moskal JR, Yamamoto H;
XX
XX WPI; 2001-353647/37.
XX
XX Novel nucleic acid molecules differentially expressed in brain cancers,
XX useful for ascertaining propensity of cell for malignant phenotype or
XX ascertaining suitability of anti-neoplastic drug candidate -

CC producing a microarray for predicting, measuring and displaying gene
 CC expression in samples derived from human placenta. The probes are useful
 CC for antenatal diagnosis of human genetic disorders.
 XX
 SQ Sequence 452 BP; 111 A; 133 C; 98 G; 110 T; 0 other;

Query Match 2.9%; Score 126; DB 22; Length 452;
 Best Local Similarity 100.0%; Pred. No. 9.8e-47;
 Matches 126; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1536 agtgcactggctgtctcctcagcagagatctaccctgtgagatagagagagccttcgc 1595
 |||||
 Db 309 agtgcactggctgtctcctcagcagagatctaccctgtgagatagagagagccttcgc 368
 Qy 1596 cttctgcaacagcttcaactggcgccaaacctcttctcagcctctctcttcgatct 1655
 |||||
 Db 369 cttctgcaacagcttcaactggcgccaaacctcttctcagcctctctcttcgatct 428
 Qy 1656 cattgg 1661
 |||||
 Db 429 cattgg 434

RESULT 4
 AAI04827
 ID AAI04827 standard; DNA; 452 BP.
 XX
 AC AAI04827;
 DT 09-OCT-2001 (first entry)
 XX
 DE Probe #4818 used to measure gene expression in human breast sample.
 XX
 KW Probe; human; breast disease; breast cancer; development disorder; ss;
 KW Inflammatory disease; proliferative breast disease; non-carcinoma tumour.
 XX
 OS Homo sapiens.
 XX
 PN WO200157270-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 29-JAN-2001; 2001WO-US00661.
 XX
 PR 04-FEB-2000; 2000US-0180312.
 PR 26-MAY-2000; 2000US-0207456.
 PR 30-JUN-2000; 2000US-0608408.
 PR 03-AUG-2000; 2000US-0632366.
 PR 21-SEP-2000; 2000US-0234687.
 PR 27-SEP-2000; 2000US-0236359.
 PR 04-OCT-2000; 2000GB-0024263.
 XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.
 XX
 PI Penn SG, Hanzel DK, Chen W, Rank DR;
 XX
 DR WPI; 2001-476286/51.
 XX
 XX Novel single exon nucleic acid probe used to measuring gene expression
 PT in a human breast -
 XX
 XX Claim 25; SEQ ID No 4818; 322pp; English.

XX The present invention relates to novel single exon nucleic acid probes.
 CC The present sequence is one such probe. The probes are useful for
 CC measuring human gene expression in a human breast sample, where the probe
 CC hybridises at high stringency to a nucleic acid expressed in the human
 CC breast. The probes are useful for predicting, diagnosing, grading,
 CC staging, monitoring and prognosing diseases of the human breast,
 CC particularly those diseases with polygenic aetiology. The diseases
 CC include: breast cancer, disorders of development, inflammatory diseases
 CC of the breast, fibrocystic changes, proliferative breast disease and

CC non-carcinoma tumours.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 452 BP; 111 A; 133 C; 98 G; 110 T; 0 other;

Query Match 2.9%; Score 126; DB 22; Length 452;
 Best Local Similarity 100.0%; Pred. No. 9.8e-47;
 Matches 126; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1536 agtgcactggctgtctcctcagcagagatctaccctgtgagatagagagagccttcgc 1595
 |||||
 Db 309 agtgcactggctgtctcctcagcagagatctaccctgtgagatagagagagccttcgc 368
 Qy 1596 cttctgcaacagcttcaactggcgccaaacctcttctcagcctctctcttcgatct 1655
 |||||
 Db 369 cttctgcaacagcttcaactggcgccaaacctcttctcagcctctctcttcgatct 428
 Qy 1656 cattgg 1661
 |||||
 Db 429 cattgg 434

RESULT 5
 AAI24251
 ID AAI24251 standard; DNA; 180 BP.
 XX
 AC AAI24251;
 DT 12-OCT-2001 (first entry)
 XX
 DE Probe #14184 for gene expression analysis in human cervical cell sample.
 XX
 KW Probe; human; microarray; gene expression; cervical epithelial cell;
 KW cervical cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200157278-A2.
 XX
 PD 09-AUG-2001.
 XX
 PF 30-JAN-2001; 2001WO-US00670.
 XX
 PR 04-FEB-2000; 2000US-0180312.
 PR 26-MAY-2000; 2000US-0207456.
 PR 30-JUN-2000; 2000US-0608408.
 PR 03-AUG-2000; 2000US-0632366.
 PR 21-SEP-2000; 2000US-0234687.
 PR 27-SEP-2000; 2000US-0236359.
 PR 04-OCT-2000; 2000GB-0024263.
 XX
 PA (MOLE-) MOLECULAR DYNAMICS INC.
 XX
 PI Penn SG, Hanzel DK, Chen W, Rank DR;
 XX
 DR WPI; 2001-488901/53.
 XX
 XX Human genome-derived single exon nucleic acid probes useful for
 PT analyzing gene expression in human cervical epithelial cells -
 XX
 XX Claim 25; SEQ ID No 14184; 487pp; English.

XX The present invention relates to human single exon nucleic acid probes
 CC (SENPs). The present sequence is one such probe. The SENPs are derived
 CC from human HeLa cells. The SENPs can be used to produce a single exon
 CC microarray, which can be used for measuring human gene expression in a
 CC sample derived from human cervical epithelial cells. By measuring gene
 CC expression, the probes are therefore useful in grading and/or staging
 CC of diseases of the cervix, notably cervical cancer.
 CC Note: The sequence data for this patent did not form part of the printed

Qy	1617	gagggcgaacctcttcacagcctctctctctctctctcgcgatctcattgg	1661
Db	61	gagggcgaacctcttcacagcctctctctctctctcgcgatctcattgg	105
RESULT 8			
AAZ60888			
ID	AAZ60888 standard; DNA; 17131 BP.		
XX	AC	AAZ60888;	
XX	AC		
XX	DT		
XX	XX	16-MAY-2000 (first entry)	
DE	DNA encoding a human geranylgeranyl pyrophosphate synthetase (hGGPPS)		
XX	XX		
KW	Human; geranylgeranyl pyrophosphate synthetase; hGGPPS; chromosome 1;		
KW	1q42-1q43 locus; prostate cancer; hGGPPS; biallelic marker;		
KW	mevalonic biosynthetic pathway; ss.		
XX	XX		
OS	Homo sapiens.		
XX	XX		
PH	Key	Location/Qualifiers	
FT	exon	486..546	
FT	FT	/*tag= a	
FT	FT	/number= 1	
FT	Intron	547..7291	
FT	FT	/*tag= b	
FT	FT	/number= 1	
FT	exon	633..826	
FT	FT	/*tag= c	
FT	FT	/number= 1bis	
FT	Intron	827..7191	
FT	FT	/*tag= d	
FT	FT	/number= 1bis	
FT	exon	7292..7384	
FT	FT	/*tag= e	
FT	FT	/number= 2	
FT	Intron	7385..13759	
FT	FT	/*tag= f	
FT	FT	/number= 2	
FT	exon	13760..13830	
FT	FT	/*tag= g	
FT	FT	/number= 3	
FT	Intron	13831..14062	
FT	FT	/*tag= h	
FT	FT	/number= 3	
FT	exon	14063..15251	
FT	FT	/*tag= i	
FT	FT	/number= 4	
XX	XX		
PN	WO200005382-A2.		
XX	XX		
PD	03-FEB-2000.		
XX	XX		
PF	23-JUL-1999;	99WO-IB01353.	
XX	XX		
PR	23-JUL-1998;	98US-0093940.	
XX	XX		
PA	(GEST) GENSET.		
XX	PI	Bougueleret L;	
XX	XX		
DR	WPI; 2000-182704/16.		
DR	P-PSDB; AAY68909.		
XX	XX		
PT	New isolated human geranyl-geranyl pyrophosphate synthetase nucleic		
PT	acids, used to develop agents for the diagnosis of, e.g. pathologies		
PT	related to a defect in the mevalonic biosynthetic pathway -		
XX	XX		
PS	Claim 1; Page 72-79; 88pp; English.		
XX	XX		
CC	The present sequence represents a genomic sequence of human		
CC	geranylgeranyl pyrophosphate synthetase (hGGPPS). The sequence		

CC	comprises the 5' regulatory region, the exons and introns, and									
CC	3' regulatory region. Two differently spliced mRNAs exist for this									
CC	gene. The first spliced mRNA is derived from a cDNA (AA260888) which									
CC	comprises exons 1, 2, 3 and 4. The second mRNA is derived from a									
CC	cDNA (AA260889) which comprises 1b1s, 2, 3, and 4. The hGGPPS gene is									
CC	located on chromosome 1, at the 1q42-1q43 locus. This chromosome 1									
CC	locus has been shown to carry a predisposing gene for prostate cancer.									
CC	The nucleic acids encoding hGGPPS can be used for screening for agents									
CC	which modulate the expression of the hGGPPS gene. Such agents can be									
CC	used in therapeutic applications. The allelic markers associated with									
CC	the hGGPPS gene can be used for the diagnosis of diseases related to									
CC	an alteration in the regulatory or coding regions of hGGPPS, such as									
CC	pathologies related to a defect in the mevalonic biosynthetic pathway									
CC	The products can also be used for detection, diagnosis and drug									
CC	screening.									
XX										
SO	Sequence 17131 BP; 5110 A; 3434 C; 3759 G; 4816 T; 12 other;									
	Query Match	1.1%	Score 50;	DB 21;	Length 17131;					
	Best Local Similarity	100.0%;	Pred. No. 1.6e-12;							
	Matches 50;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps					
Oy	2412 ggggtcaagcgattctctgcctcagcctcctaagtagctgggtacag 2461									
Db	16804 ggggtcaagcgattctctgcctcagcctcctaagtagctgggtacag 16853									
RESULT 9										
AAA45104/c										
ID	AAA45104 standard; cDNA; 454 BP.									
XX										
AC	AAA45104;									
XX										
DT	21-AUG-2000 (first entry)									
XX										
DE	Human secreted expressed sequence tag SEQ ID NO:1679.									
XX										
KW	Human; mouse; chicken; rat; secreted expressed sequence tag; sEST;									
KW	expressed sequence tag; EST; probe; chemotactic; proliferative;									
KW	immunomodulatory; haematopoietic; chemokinetic; analgesic; haemostatic;									
KW	thrombolytic; antiinflammatory; cytostatic; antibacterial; antifungal;									
KW	antiviral; antidiabetic; antiasthmatic; vulnery; antiparkinsonian;									
KW	antiulcer; osteopathic; neuroprotective; nootropic; antipsoriatic;									
KW	cerebroprotective; anticonvulsant; antidepressant; gene therapy;									
KW	vaccine; autoimmune disorder; multiple sclerosis; allergic condition;									
KW	insulin dependent diabetes; asthma; myeloid cell deficiency; ulcer;									
KW	lymphoid cell deficiency; burn; osteoporosis; osteoarthritis;									
KW	central nervous system disorder; Alzheimer's disease; stroke;									
KW	Parkinson's disease; Huntington's disease; coagulation disorder;									
KW	haemophilia; thrombosis; inflammatory disorder; Crohn's disease;									
KW	tumour; infection; depression; psoriasis; ss.									

AA	
OS	Homo sapiens.
XX	
XX	
PN	WO200021991-A1.
XX	
XX	
PD	20-APR-2000.
XX	
XX	
PF	15-OCT-1999; 99WO-US24206.
XX	
XX	
PR	15-OCT-1998; 98US-0104436.
XX	
XX	
PA	(GEMY) GENETICS INST INC.
XX	
PI	Jacobs K, McCoy JM, LaVallie ER, Collins-Racie LA, Evans C;
PI	Meiberg D, Treacy M, Bowman MR;
XX	
DR	WPI; 2000-317938/27.
XX	
PT	Isolated polynucleotides, and encoded proteins, comprising secreted
PT	expressed sequence tags (ESTs), useful for treating various disorders
PT	such as autoimmune infections, and central nervous system disorders -

Sequence 21636 BP; 7160 A; 3812 C; 4168 G; 6463 T; 33 other;

Qy 2389 gctcactgcaacctccacttccctctctgggttcaagcgattctctcgctca 2436
|||
Db 9950 gctcactgcaacctccacttccctctctgggttcaagcgattctctcgctca 9997

XX	(CORI-) CORIXA CORP.	
PA		
XX		
PI	Yuqiu J, Dillon DC, Mitcham JL, Xu J, Harlocker SL;	
XX		
DR	WPI; 2001-122627/13.	

An isolated polypeptide useful for the treatment and diagnosis of tumors e.g. breast cancer comprises at least an immunogenic portion of a breast tumor protein -

XX Claim 66; Page 189; 238pp; English.

XX The present invention provides the coding sequences and some protein

CC sequences of proteins associated with breast cancer in humans. These

CC sequences can be used in the diagnosis and treatment of cancers,

CC particularly breast tumours.

XX

SO Sequence 241 BP; 75 A; 24 C; 18 G; 112 T; 12 other;

Query Match 1.0%; Score 46; DB 22; Length 241;

Best Local Similarity 100.0%; Pred. No. 1.1e-10;

Matches 46; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 4214 agttattattattgtgaagtgtgtgcaacaaacataccctttat 4259

Db 189 AGTTATTATTATTGTAAGTTGTGTGCAACAACATACCTTTAT 144

RESULT 12

AAF65548/C

ID AAF65548 standard; cDNA; 376 BP.

XX

AC AAF65548;

XX

DT 09-APR-2001 (first entry)

XX

DE Novel human polynucleotide, SEQ ID NO: 1304.

XX

KW Human; cytostatic; gene therapy; colon cancer; prostate cancer;

KW breast cancer; lung cancer; cancer detection; ss.

XX

OS Homo sapiens.

XX

WO200102568-A2.

XX

11-JAN-2001.

XX

30-JUN-2000; 2000WO-US18374.

XX

02-JUL-1999; 99US-0142310.

PR

02-JUL-1999; 99US-0142311.

PR

XX

PA (CHIR) CHIRON CORP.

PA

(HYSE-) HYSEQ INC.

XX

Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam A;

PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Lamson G, Drmanac R;

PI Crkenjakov R, Drmanac S, Dickson M, Labat I, Leshkowitz D;

PI Kita D, Garcia V, Jones LW, Strache-Crain B;

XX

WPI; 2001-091805/10.

DR

XX

Library of polynucleotides for diagnosing a cancerous state of a

PT mammalian cell and detecting cancer, particularly of the colon or

PT prostate, comprises 3351 human polynucleotide sequences -

XX

Claim 9; Page 730; 1046pp; English.

XX

The present sequence is one of 3351 sequences in a library of human

CC polynucleotides. The library is used to detect differentially expressed

CC genes correlated with a cancerous state of a mammalian cell and can

CC detect colon, prostate, breast and lung cancer. The library can be used

CC to produce probes for detection of mRNA and to produce additional copies

CC of the polynucleotides. The probes can be used for chromosome mapping of

CC the polynucleotide and for detection of transcription levels. Ribozymes

CC or antisense oligonucleotides can be generated. The polynucleotides and

CC their gene products are used as genetic or biochemical markers (e.g. in

CC blood or tissues) that will detect the earliest changes along the

CC carcinogenesis pathway and/or monitor the efficacy of therapies and

CC preventive interventions. The polynucleotides, polypeptides and

CC antibodies against them can be used in pharmaceutical compositions to

CC treat the cancers and proliferative disorders such as neoplasia,

CC dysplasia and hyperplasia.

XX

SO Sequence 376 BP; 112 A; 87 C; 109 G; 68 T; 0 other;

Query Match 1.0%; Score 46; DB 22; Length 376;

Best Local Similarity 100.0%; Pred. No. 1.1e-10;

Matches 46; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2412 ggggttcaagcgtctcctcgcctcgcctcctaaagtagctggatt 2457

Db 174 GGGTTCAGGAGATTCTCTCGCTCAGCCTCCTAAGTAGCTGGATT 129

RESULT 13

AXX85026/C

ID AAX85026 standard; DNA; 1242 BP.

XX

AC AAX85026;

XX

DT 30-JUL-1999 (first entry)

XX

DE Human secreted protein gene No. 94.

XX

KW Human; secreted protein; fusion protein; gene therapy; protein therapy;

KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;

KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;

KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;

KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;

KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;

KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;

KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.

XX

Homo sapiens.

XX

WO9924836-A1.

XX

20-MAY-1999.

XX

04-NOV-1998; 98WO-US23435.

XX

17-NOV-1997; 97US-0066100.

PR

07-NOV-1997; 97US-0064900.

PR

07-NOV-1997; 97US-0064908.

PR

07-NOV-1997; 97US-0064911.

PR

07-NOV-1997; 97US-0064912.

PR

07-NOV-1997; 97US-0064983.

PR

07-NOV-1997; 97US-0064984.

PR

07-NOV-1997; 97US-0064985.

PR

07-NOV-1997; 97US-0064987.

PR

07-NOV-1997; 97US-0064988.

PR

17-NOV-1997; 97US-0066090.

PR

17-NOV-1997; 97US-0066094.

PR

17-NOV-1997; 97US-0066095.

PR

17-NOV-1997; 97US-0066089.

XX

(HUMA-) HUMAN GENOME SCI INC.

XX

Carter KC, Ebner R, Endress GA, Feng P, Janat F;

PI Kyaw H, Lafleur DW, Moore PA, Ni J, Olsen HS, Rosen CA;

PI Ruben SM, Shi Y, Soppet DR, Wei Y;

XX

WPI; 1999-337740/28.

DR

P-PSDB; AAY27660.

XX

New human secreted proteins and coding sequences useful for treating

PT disorders of the immune system and hyperproliferative disorders

XX

Claim 1; Page 331; 507pp; English.

XX

This sequence represents a nucleic acid molecule which encodes a

CC secreted human protein. The gene number is given in the descriptor line.

CC The gene can be used to generate fusion proteins by linking to the gene
 CC to a human immunoglobulin Fc portion (e.g. AA84924) for increasing the
 CC stability of the fused protein as compared to the human protein only.
 CC The invention relates to 125 novel genes and their fragments (nucleic
 CC acid sequences: AA84933-X85057; amino acid sequences AAY27567-Y27933)
 CC which are useful for preventing, treating or ameliorating medical
 CC conditions e.g. by protein or gene therapy. Also, pathological
 CC conditions can be diagnosed by determining the amount of the new
 CC polypeptides in a sample or by determining the presence of mutations in
 CC the new polynucleotides. Specific uses are described for each of the 125
 CC polynucleotides, based on which tissues they are most highly expressed in
 CC (see AA84933 for described uses).

XX Sequence 1242 BP; 356 A; 259 C; 251 G; 373 T; 3 other;

Query Match 1.0%; Score 45; DB 20; Length 1242;
 Best Local Similarity 100.0%; Pred. No. 2.9e-10;
 Matches 45; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2488 tatttttagcagagatgggtttcaactgtgttgccaggctgttc 2532
 |||||
 DB 1048 TATTTTAGCAGAGATGGGTTTCACTGTCTTGCCAGGCTGTC 1004

RESULT 14

AAH10383
 ID AAH10383 standard; cDNA; 545 BP.

XX AAH10383;

DT 26-JUN-2001 (first entry)

DE Human cDNA clone (3'-primer) SEQ ID NO:7218.

XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.

XX Homo sapiens.

PN EP1074617-A2.

XX 07-FEB-2001.

XX 28-JUL-2000; 2000EP-0116126.

XX 29-JUL-1999; 99JP-0248036.

XX 27-AUG-1999; 99JP-0300253.

XX 11-JAN-2000; 2000JP-0118776.

XX 02-MAY-2000; 2000JP-0183767.

XX 09-JUN-2000; 2000JP-0241899.

XX (HELI-) HELIX RES INST.

PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

DR WPI; 2001-318749/34.

XX Primer sets for synthesizing polynucleotides, particularly the 5602

XX full-length cDNAs defined in the specification, and for the detection

XX and/or diagnosis of the abnormality of the proteins encoded by the

XX full-length cDNAs.

PS Claim 3; SEQ ID 7218; 2537pp + CD ROM; English.

XX The present invention describes primer sets for synthesizing 5602

XX full-length cDNAs defined in the specification. Where a primer set

XX comprises: (a) an oligo-dT primer and an oligonucleotide complementary

XX to the complementary strand of a polynucleotide which comprises one of

XX the 5602 nucleotide sequences defined in the specification, where the

XX oligonucleotide comprises at least 15 nucleotides; or (b) a combination

CC sequence and an oligonucleotide comprising a sequence complementary to a
 CC polynucleotide which comprises a 3'-end sequence, where the
 CC oligonucleotide comprises at least 15 nucleotides and the combination of
 CC the 5'-end sequence/3'-end sequence is selected from those defined in
 CC the specification. The primer sets can be used in antisense therapy and
 CC in gene therapy. The primers are useful for synthesizing polynucleotides,
 CC particularly full-length cDNAs. The primers are also useful for the
 CC detection and/or diagnosis of the abnormality of the proteins encoded by
 CC the full-length cDNAs. The primers allow obtaining of the full-length
 CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
 CC AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to
 CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
 CC represent oligonucleotides, all of which are used in the exemplification
 CC of the present invention.

XX Sequence 545 BP; 121 A; 136 C; 121 G; 159 T; 8 other;

Query Match 1.0%; Score 44; DB 22; Length 545;
 Best Local Similarity 100.0%; Pred. No. 8.4e-10;
 Matches 44; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2415 ttcaagcgattctcgtcctcagcctccttaagtagctgggatta 2458
 |||||

DB 86 ttcaagcgattctcgtcctcagcctccttaagtagctgggatta 129

RESULT 15

AAH17513/c

ID AAH17513 standard; cDNA; 2609 BP.

XX AAH17513;

DT 26-JUN-2001 (first entry)

DE Human cDNA sequence SEQ ID NO:16986.

XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.

XX Homo sapiens.

PN EP1074617-A2.

XX 07-FEB-2001.

XX 28-JUL-2000; 2000EP-0116126.

XX 29-JUL-1999; 99JP-0248036.

XX 27-AUG-1999; 99JP-0300253.

XX 11-JAN-2000; 2000JP-0118776.

XX 02-MAY-2000; 2000JP-0183767.

XX 09-JUN-2000; 2000JP-0241899.

XX (HELI-) HELIX RES INST.

PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

DR WPI; 2001-318749/34.

XX Primer sets for synthesizing polynucleotides, particularly the 5602

XX full-length cDNAs defined in the specification, and for the detection

XX and/or diagnosis of the abnormality of the proteins encoded by the

XX full-length cDNAs.

PS Claim 8; SEQ ID 16986; 2537pp + CD ROM; English.

XX The present invention describes primer sets for synthesizing 5602

XX full-length cDNAs defined in the specification. Where a primer set

XX comprises: (a) an oligo-dT primer and an oligonucleotide complementary

XX to the complementary strand of a polynucleotide which comprises one of

XX the 5602 nucleotide sequences defined in the specification, where the

XX oligonucleotide comprises at least 15 nucleotides; or (b) a combination

THIS PAGE BLANK (USPTO)